摘要
目的 :评价CEA、AFP、CA - 12 5联检对妇科肿瘤的诊治价值。方法 :测定采用放射免疫分析法。结果 :妇科恶性肿瘤中CA - 12 5阳性率 80 85 % (38/ 47) ;CEA阳性率 8 5 1% (4 / 47) ;AFP阳性率 14 89(7/ 47)。三项联检阳性检出率 95 7% (4 5 / 47)。妇科良性肿瘤CA - 12 5均值 2 2 0 2± 15 35 ,恶性肿瘤CA - 12 5均值2 13 5 9± 12 7 2 6 ,二者比较有显著性差异 (P <0 0 1)。术后CA - 12 5均值为 34 2 3± 2 0 5 2 ,与手术前 2 13 5 9±12 7 2 6比较P <0 0 1。结论 :CEA、AFP、CA - 12 5联检有助于提高妇科恶性肿瘤诊断符合率 ,CA - 12 5可作为术后长期追踪检测的指标。
Objective To evaluate the value of combined analysis of serum CA-125, CEA and AFP for the diagnosis and therapy in gynecologic tumors. Methods Measurements were carried out by radioimmunoassay. Results The positive rates of CA-125, CEA and AFP were respectively 80.85%(38/47), 8.51%(4/47) and 14.89%(7/47) in gynecologic malignancies. The combined positive rate of the three above-mentioned was 95.7%(45/47). The average level of CA-125 was 22.02±15.35 in benign tumor and 213±127 26 in malignant tumor( P <0 01). The average level of CA-125 dropped from 213 59±127 26 to 34 23±20 52 postoperatively ( P <0 01). Conclusion The combined analysis of serum CA-125, CEA and AFP could improve the diagnostic accuracy in gynecologic tumocs. CA-125 could also used for long-time monitoring after surgery.
出处
《放射免疫学杂志》
CAS
2001年第6期326-327,共2页
Journal of Radioimmanology
